Viatris (NSDQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled in favor of Mylan in an EpiPen class action. Mylan, which Pfizer combined with its Upjohn business to form Viatris in November 2020, received a favorable ruling in substantial part that dismissed all of the plaintiffs’ claims under the federal RICO […]
Orum Therapeutics raises $84M for targeted protein degrader payloads
Orum Therapeutics announced today that it closed an $84 million Series B financing for its targeted protein degraders for treating cancer. Boston-based Orum’s funding round includes a previously announced $30 million financing, plus another $54 million in new funds led by IMM Investment and joined by new investors KDB Investment and Atinum, among others. Existing […]
Teva launches first U.S. generic Perforomist inhaled COPD treatment
Teva Pharmaceuticals (NYSE:TEVA) announced the U.S. launch of the first generic version of the twice-daily Perforomist inhalation solution. Parsippany, N.J.-based Teva Pharmaceuticals — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries Ltd. — launched the formoterol fumarate inhalation solution (20 mcg/2 mL) with an indication for treating bronchoconstriction in patients with chronic obstructive […]
Soleo Health appoints new VP of business development, industry relations
Soleo Health announced today that it appointed Becky Rand as its VP of business development and industry relations. Rand’s responsibilities include initiating and maintaining relationships with pharmaceutical manufacturers and biotechnology companies while also looking to broaden the company’s portfolio of exclusive and limited drug distribution partnerships and other strategic initiatives. Frisco, Texas-based Soleo Health is […]
Pear Therapeutics to go public via merger with SPAC
Prescription digital therapeutics pioneer Pear Therapeutics announced today that it will go public by merging with a SPAC called Thimble Point Acquisition Corp. Boston-based Pear Therapeutics’ combination with the special purpose acquisition company (SPAC), whose management team is associated with the Pritzker Vlock Family Office, will result in a combined company named Pear Holdings Corp. […]
Glytec names Nausheen Moulana as chief technology officer
Cloud-based insulin management software developer Glytec announced today that it appointed Nausheen Moulana as its chief technology officer. In the role of CTO, Moulana will be responsible for Glytec’s product and technology vision, strategy and execution. She will lead the company’s product development teams — focusing on enhancements in provider workflows, electronic health record (EHR) […]
Smiths Medical recalls some insulin syringes over skewed graduation marking
Smiths Medical announced today that it issued recall notices for its Jelco Hypodermic Needle-Pro fixed needle insulin syringes. Minneapolis-based Smiths Medical became aware of specific models and lots of the Jelco Hypodermic Needle-Pro fixed needle syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. The company identified markings skewed upward […]
Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 Capital and Population Health Partners, while other new and existing investors participated, too. According to a news […]
Diabetes Center Berne launches open innovation challenge for diabetes tech
The Diabetes Center Berne today announced the launch of an initiative to develop technology to address the treatment of diabetes. DCB is seeking innovators, co-creators, scientists and members of the diabetes community to join the company’s innovation challenge and join its community of diabetes technology developers. The center requested anyone ranging from members of start-ups, […]
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology. The company designed the investigational mdc-STM product […]
